Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesmilifene + EC vs EC in metastatic breast cancer
NCT00099281Phase 3Terminated
- Sponsor
- YM BioSciences
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tesmilifene in breast cancer, sponsored by YM BioSciences. Primary endpoint: Overall Survival. Started May 2004; status: terminated.
02
Drugs
tesmilifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00099281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099281.